sponsored
PatientsVille.com Logo

PatientsVille

Compazine Medical Research Studies

Up-to-date List of Compazine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Compazine Medical Research Studies

Rank Status Study
1 Unknown  Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache
Condition: Migraine Headache
Intervention: Drug: Octreotide
Outcome Measures: Patient Satisfaction;   Improvement of Pain;   Improvement of Nausea
2 Recruiting Bupivacaine for Benign Headache in the ED
Condition: Benign Headache
Interventions: Drug: 0.5% bupivacaine;   Drug: Standard Care
Outcome Measures: Length of stay;   Incidence of immediate and post-discharge complications.;   Symptomatic relief of headache
3 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
Outcome Measures: Complete Response, Acute Phase (Day 1), Cycle 1;   Complete Response, Delayed Phase (Days 2 to 11), Cycle 1;   Complete Response - Cycle 2 and beyond;   No Significant Nausea - Cycle 2 and beyond;   Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond;   Frequency of common adverse events associated with anti-emetics;   Severity of common adverse events associated with anti-emetics
4 Not yet recruiting IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Conditions: Headache Disorders, Primary;   Migraine With Aura;   Migraine Without Aura;   Tension-Type Headache
Intervention:
Outcome Measures: Proportion of patients with significant pain reduction;   Proportion of patients who are satisfied with IndoProCaf treatment;   Time to significant pain reduction;   Proportion of patients with significant pain reduction in case of first dose no response;   Proportion of patients with significant pain reduction in case of headache relapse;   Proportion of patients who are satisfied with different medicines previously used for headache attack
5 Recruiting Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine;   Drug: Fosaprepitant Placebo;   Drug: Dexamethasone;   Drug: Ondansetron;   Drug: Dexamethasone Placebo;   Drug: Ondansetron Placebo;   Drug: Rescue Therapy
Outcome Measures: Number of participants with Complete Response from 25 to 120 hours after initiation of MEC.;   Number of participants with infusion-site thrombophlebitis;   Number of participants with severe infusion-site reactions, including site pain, or site redness (erythema) or site hardness (induration);   Number of participants with Complete Response from 0 to 120 hours after initiation of MEC;   Number of participants with Complete Response from 0 to 24 hours after initiation of MEC;   Number of participants with No Vomiting from 0 to 120 hours after initiation of MEC

These studies may lead to new treatments and are adding insight into Compazine etiology and treatment.

A major focus of Compazine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Compazine